Earlier this season, we saw evidence of a new SRAM 12-speed road group coming, thanks to public sightings of Jeremy Powers and Wout van Aert’s bikes in Rochester, Gavere and Tabor. Now we’ve got the ...

AXIS Capital trades at $97 per share and has stayed right on track with the overall market, gaining 8.7% over the last six months. At the same time, the S&P 500 has returned 4.1%. Is there a buying ...

The latest SRAM RED AXS, which debuted in May 2024, took everything good about the prior Force & Rival updates, made it better, then took it further. Not only did the hood shapes improve like its ...

TSLQ & NVDS blazed the trail for U.S.-listed single stock ETFs empowering traders to express bearish short-term views on Tesla and Nvidia stock TSLQ is one of the fastest-growing ETFs of the past year ...

Axsome's AXS-05 shows strong efficacy in treating Alzheimer's Disease Agitation, with significant CMAI score reductions in multiple Phase 3 trials. The FDA has greenlit Axsome to submit an sNDA for ...

AXS-07, targeting chronic migraine, has shown promising results in Phase 3 trials but faced a CRL from the FDA due to CMC issues. The FDA has set a new PDUFA date for AXS-07 on January 31, 2025, ...